Gene therapy for Friedreich’s ataxia
Nature Medicine
2014년4월7일
A gene therapy method corrects the heart defects in a mouse model of Friedreich’s ataxia-which damages both the heart and the nervous system and leads to movement problems. These findings, published this week in Nature Medicine, have potential application for the therapy of individuals with Friedreich’s ataxia.
Individuals with Friedreich’s ataxia harbor mutations in the gene encoding frataxin, an essential mitochondrial protein, and have a variety of symptoms, including neurodegeneration, cardiomyopathy and diabetes. The major cause of mortality in these individuals is heart failure.
Using mice lacking frataxin in the heart, Helene Puccio and her colleagues demonstrate that frataxin gene therapy can correct mitochondrial metabolism and reverse heart damage, raising the possibility of a gene therapy treatment for this disease.
doi: 10.1038/nm.3510
리서치 하이라이트
-
6월24일
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
6월23일
Scientific community: Women credited less than men in scientific paper authorshipNature
-
6월17일
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
6월16일
An exercise-inducible molecule that suppresses appetiteNature
-
6월16일
Cancer: Signatures of structural genomic variation in cancerNature
-
6월10일
Animals: Genetic clues to how dogs became man’s best friendsScientific Reports